Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND IBUPROFEN versus SOLARAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE AND IBUPROFEN versus SOLARAZE.
HYDROCODONE BITARTRATE AND IBUPROFEN vs SOLARAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a semisynthetic opioid agonist with selectivity for mu-opioid receptors, producing analgesia and sedation. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby providing anti-inflammatory, analgesic, and antipyretic effects.
Solaraze (diclofenac sodium) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation and pain. In actinic keratosis, it may also induce apoptosis and decrease keratinocyte proliferation.
One tablet (hydrocodone bitartrate 5 mg/ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
Apply 0.5 mL (1 unit dose) topically to actinic keratoses twice daily for 2 to 4 weeks, then 1 week off, repeat for a total of 3 treatment cycles.
None Documented
None Documented
Hydrocodone: 3.8-4.5 hours (immediate release); Ibuprofen: 1.8-2.5 hours (racemic, S-enantiomer slightly shorter). Clinical context: dosing every 4-6 hours due to hydrocodone half-life.
Following topical application, the terminal elimination half-life of diclofenac from plasma is approximately 12 hours (range 8-15 hours). This reflects the slow absorption and distribution from the skin depot, with clinical relevance for twice-daily dosing.
Hydrocodone: primarily renal (60-70% as metabolites, <12% unchanged); Ibuprofen: primarily renal (90% as metabolites and conjugates, <1% unchanged), minor biliary/fecal.
Solaraze (diclofenac sodium 3% gel) is primarily eliminated via hepatic metabolism followed by renal excretion of metabolites. Approximately 65% of a dose is excreted in urine as conjugated metabolites, with less than 1% as unchanged drug. About 35% is eliminated in feces via biliary excretion of metabolites.
Category D/X
Category C
NSAID
NSAID